In previous studies, the loss of SMAD4 function was an independent prognostic factor for decreased recurrence-free and overall survival (OS) in CRC patients, particularly those with advanced-stage disease [20–23]. This evidence concerns the gene SMAD4 and colorectal carcinoma.